401 related articles for article (PubMed ID: 32761153)
1. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019.
Maniakas A; Dadu R; Busaidy NL; Wang JR; Ferrarotto R; Lu C; Williams MD; Gunn GB; Hofmann MC; Cote G; Sperling J; Gross ND; Sturgis EM; Goepfert RP; Lai SY; Cabanillas ME; Zafereo M
JAMA Oncol; 2020 Sep; 6(9):1397-1404. PubMed ID: 32761153
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience.
Wu SS; Lamarre ED; Yalamanchali A; Brauer PR; Hong H; Reddy CA; Yilmaz E; Woody N; Ku JA; Prendes B; Burkey B; Nasr C; Skugor M; Heiden K; Chute DJ; Knauf JA; Campbell SR; Koyfman SA; Geiger JL; Scharpf J
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):300-309. PubMed ID: 36757708
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
Rao SN; Zafereo M; Dadu R; Busaidy NL; Hess K; Cote GJ; Williams MD; William WN; Sandulache V; Gross N; Gunn GB; Lu C; Ferrarotto R; Lai SY; Cabanillas ME
Thyroid; 2017 May; 27(5):672-681. PubMed ID: 28068873
[TBL] [Abstract][Full Text] [Related]
4. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF
Zhao X; Wang JR; Dadu R; Busaidy NL; Xu L; Learned KO; Chasen NN; Vu T; Maniakas A; Eguia AA; Diersing J; Gross ND; Goepfert R; Lai SY; Hofmann MC; Ferrarotto R; Lu C; Gunn GB; Spiotto MT; Subbiah V; Williams MD; Cabanillas ME; Zafereo ME
Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
[No Abstract] [Full Text] [Related]
5. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
Jannin A; Giudici F; de la Fouchardière C; Al Ghuzlan A; Wassermann J; Chougnet CN; Drui D; Godbert Y; Ilouz F; Bardet S; Zanetta S; Roudaut N; Batisse Lignier M; Groussin L; Klein M; Zerdoud S; Lamartina L; Baudin E; Decaussin-Petrucci M; Leteurtre E; Borson Chazot F; Do Cao C; Borget I; Hadoux J;
Thyroid; 2023 Oct; 33(10):1190-1200. PubMed ID: 37855745
[No Abstract] [Full Text] [Related]
6. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.
Pezzi TA; Mohamed ASR; Sheu T; Blanchard P; Sandulache VC; Lai SY; Cabanillas ME; Williams MD; Pezzi CM; Lu C; Garden AS; Morrison WH; Rosenthal DI; Fuller CD; Gunn GB
Cancer; 2017 May; 123(9):1653-1661. PubMed ID: 28026871
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
[TBL] [Abstract][Full Text] [Related]
8. Impact of Timeliness of Resection and Thyroidectomy Margin Status on Survival for Patients with Anaplastic Thyroid Cancer: An Analysis of 335 Cases.
Goffredo P; Thomas SM; Adam MA; Sosa JA; Roman SA
Ann Surg Oncol; 2015 Dec; 22(13):4166-74. PubMed ID: 26271394
[TBL] [Abstract][Full Text] [Related]
9. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
Park J; Jung HA; Shim JH; Park WY; Kim TH; Lee SH; Kim SW; Ahn MJ; Park K; Chung JH
Eur J Endocrinol; 2021 May; 184(6):837-845. PubMed ID: 33852431
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component.
Wong KS; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Barletta JA
Endocr Pathol; 2020 Sep; 31(3):283-290. PubMed ID: 32445173
[TBL] [Abstract][Full Text] [Related]
11. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.
Wendler J; Kroiss M; Gast K; Kreissl MC; Allelein S; Lichtenauer U; Blaser R; Spitzweg C; Fassnacht M; Schott M; Führer D; Tiedje V
Eur J Endocrinol; 2016 Dec; 175(6):521-529. PubMed ID: 27926471
[TBL] [Abstract][Full Text] [Related]
12. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
[TBL] [Abstract][Full Text] [Related]
14. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012.
Brignardello E; Palestini N; Felicetti F; Castiglione A; Piovesan A; Gallo M; Freddi M; Ricardi U; Gasparri G; Ciccone G; Arvat E; Boccuzzi G
Thyroid; 2014 Nov; 24(11):1600-6. PubMed ID: 25110922
[TBL] [Abstract][Full Text] [Related]
15. Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.
Jonker PKC; Turchini J; Kruijff S; Lin JF; Gill AJ; Eade T; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Tsang V; Glover A; Sidhu S; Sywak M
Ann Surg Oncol; 2021 Nov; 28(12):7520-7530. PubMed ID: 34032961
[TBL] [Abstract][Full Text] [Related]
16. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
Prasongsook N; Kumar A; Chintakuntlawar AV; Foote RL; Kasperbauer J; Molina J; Garces Y; Ma D; Wittich MAN; Rubin J; Richardson R; Morris J; Hay I; Fatourechi V; McIver B; Ryder M; Thompson G; Grant C; Richards M; Sebo TJ; Rivera M; Suman V; Jenkins SM; Smallridge RC; Bible KC
J Clin Endocrinol Metab; 2017 Dec; 102(12):4506-4514. PubMed ID: 29029287
[TBL] [Abstract][Full Text] [Related]
17. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
18. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.
Wächter S; Vorländer C; Schabram J; Mintziras I; Fülber I; Manoharan J; Holzer K; Bartsch DK; Maurer E
Eur Arch Otorhinolaryngol; 2020 May; 277(5):1507-1514. PubMed ID: 32060602
[TBL] [Abstract][Full Text] [Related]
20. Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.
Liu TR; Xiao ZW; Xu HN; Long Z; Wei FQ; Zhuang SM; Sun XM; Xie LE; Mu JS; Yang AK; Zhang GP; Fan Y
PLoS One; 2016; 11(10):e0164840. PubMed ID: 27760217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
